Karyopharm Therapeutics Inc. — 2015 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015; filed March 15, 2016. The filing is an annual report, not a standalone fourth-quarter filing. Financial amounts below are in U.S. dollars; annual statements are audited and quarterly figures are unaudited.
Business context
Karyopharm is a clinical-stage pharmaceutical company developing small-molecule SINE compounds that inhibit XPO1. Its lead candidate, oral selinexor (KPT-330), was being studied in multiple hematologic and solid tumor indications. The company had no revenue from drug sales; its reported revenue came from grants and research agreements. Other pipeline programs included KPT-8602, verdinexor (KPT-335), KPT-350 and KPT-9274.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Contract and grant revenue | $0.25 million | $0.23 million |
| Research and development expense | $97.7 million | $60.1 million |
| General and administrative expense | $21.6 million | $15.9 million |
| Operating loss | $119.1 million | $75.8 million |
| Net loss | $118.2 million | $75.8 million |
| Net loss per share, basic and diluted | $3.32 | $2.43 |
| Net cash used in operating activities | $94.0 million | $51.4 million |
FY 2015 research and development costs rose about 63%, principally from expanded selinexor clinical trials, pipeline work and increased staffing. Operating expenses totaled $119.3 million. No meaningful product-sales margins were reported because the company had not commercialized a drug.
At December 31, 2015, cash and cash equivalents were $58.4 million, short-term investments $117.3 million, long-term investments $33.9 million and restricted cash $0.5 million. Working capital was $162.5 million and total assets were $215.4 million. Total liabilities were $17.1 million; the balance sheet reports no borrowings or other interest-bearing debt. The company raised $90.8 million net through a January 2015 stock offering and $1.5 million net through its at-the-market offering by year-end. Financing activities provided $92.7 million; investing activities used $90.8 million, largely reflecting investment purchases and maturities.
Management stated that available cash and investments were expected to fund its operating plan into mid-2018. However, a note to the financial statements says resources would fund the current plan through at least January 1, 2017. The filing therefore contains differing runway statements that investors should reconcile.
Material changes and operating developments
- Net loss increased 56% from 2014, while operating cash use increased about 83%.
- Cash, cash equivalents and short- and long-term investments totaled approximately $209.5 million at year-end, down from $214.4 million in 2014; the broader reported cash, restricted cash and investment total was $210.0 million.
- Selinexor clinical activity expanded, including the Phase 2b STORM multiple myeloma study and randomized Phase 2/3 SEAL liposarcoma study. The company planned to start the SCORE multiple myeloma combination trial in mid-2016.
- KPT-8602 entered human testing in early 2016; the company expected to begin KPT-9274 testing around mid-2016. Verdinexor completed a Phase 1 study in healthy volunteers.
- Common shares outstanding increased to 35.9 million from 32.7 million, primarily reflecting equity financing and employee-related issuances.
Outlook, commentary and principal risks
Management expected operating expenses and losses to rise as clinical programs advanced, with no drug-sales revenue expected for several years, if ever. Planned milestones included STORM topline response data in mid-2016; STOMP dose findings in late 2016; and SOPRA interim analysis in late 2016. These were forecasts, not guarantees.
Management described early evidence of activity for selinexor but emphasized that clinical data were preliminary and, in some cases, unaudited investigator-reported results. Reported risks include trial failure or delay, patient enrollment and safety issues, regulatory uncertainty, dependence on external manufacturers and research organizations, lack of backup drug supply arrangements, need for additional capital, and uncertainty about commercialization, reimbursement and market acceptance. Common selinexor adverse events included nausea, fatigue, anorexia, vomiting and thrombocytopenia; higher doses in heavily pretreated AML patients were associated with increased sepsis concerns, prompting a dose reduction in SOPRA. The filing also notes potential worsening of pre-existing cataracts. No material legal proceedings were reported.
The company reported no material off-balance-sheet arrangements and $9.5 million in minimum operating lease obligations. Its financial statements received an unqualified audit opinion; management concluded disclosure controls and internal control over financial reporting were effective, but the auditor did not provide an ICFR attestation.
Most important facts for investors to verify
- Reconcile the stated cash runway: MD&A forecasts funding into mid-2018, while the financial-statement note cites at least January 1, 2017.
- Track actual selinexor trial outcomes, particularly STORM, SOPRA, SEAL and SCORE, and distinguish interim or unaudited findings from final controlled-trial results.
- Monitor cash burn, future equity issuance and dilution, and the timing and terms of any additional financing.
- Assess dose-related safety, especially hematologic adverse events and sepsis in AML, and whether dose adjustments preserve efficacy.
- Confirm manufacturing capacity and supply redundancy, regulatory requirements, and the ability to establish commercial infrastructure if a candidate is approved.